Literature DB >> 11506886

Genetic animal models: focus on schizophrenia.

R R Gainetdinov1, A R Mohn, M G Caron.   

Abstract

The neurobiology of schizophrenia remains poorly understood. Symptoms of schizophrenia are classically thought to be associated with an imbalance of the dopaminergic system. However, the contribution of other neurotransmitters, in particular glutamate, has been increasingly appreciated. The role of individual components of neurotransmitter systems in aberrant behaviors can be experimentally tested in transgenic animals. Dopamine transporter knockout mice display persistently elevated dopaminergic tone and therefore might be appropriate substrates to evaluate the dopamine hypothesis. Similarly, NMDA receptor-deficient mice can be used to evaluate the glutamate hypothesis of schizophrenia. In this review we discuss how such animal models might be relevant for understanding the neurochemical underpinnings of certain manifestations of schizophrenia.

Entities:  

Mesh:

Year:  2001        PMID: 11506886     DOI: 10.1016/s0166-2236(00)01886-5

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  60 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 2.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

Review 3.  Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?

Authors:  Craig M Powell; Tsuyoshi Miyakawa
Journal:  Biol Psychiatry       Date:  2006-06-15       Impact factor: 13.382

4.  No effect of sex on ethanol intake and preference after dopamine transporter (DAT) knockdown in adult mice.

Authors:  Amine Bahi; Jean-Luc Dreyer
Journal:  Psychopharmacology (Berl)       Date:  2018-12-12       Impact factor: 4.530

5.  Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice.

Authors:  D J Gerber; T D Sotnikova; R R Gainetdinov; S Y Huang; M G Caron; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

6.  Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats.

Authors:  Tomohiro Tatsuta; Nobue Kitanaka; Junichi Kitanaka; Yoshio Morita; Motohiko Takemura
Journal:  Neurochem Res       Date:  2005-11       Impact factor: 3.996

7.  Comprehensive behavioral analysis of calcium/calmodulin-dependent protein kinase IV knockout mice.

Authors:  Keizo Takao; Koichi Tanda; Kenji Nakamura; Jiro Kasahara; Kazuki Nakao; Motoya Katsuki; Kazuo Nakanishi; Nobuyuki Yamasaki; Keiko Toyama; Minami Adachi; Masahiro Umeda; Tsutomu Araki; Kohji Fukunaga; Hisatake Kondo; Hiroyuki Sakagami; Tsuyoshi Miyakawa
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

Review 8.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

9.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

10.  Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social contact duration in two social interaction tests.

Authors:  Naoki Matsuo; Koichi Tanda; Kazuo Nakanishi; Nobuyuki Yamasaki; Keiko Toyama; Keizo Takao; Hiroshi Takeshima; Tsuyoshi Miyakawa
Journal:  Front Behav Neurosci       Date:  2009-05-07       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.